ACTIVE IMPLANTABLE MEDICAL DEVICES MARKET ANALYSIS

Active Implantable Medical Devices Market, By Product (Implantable Cardioverter Defibrillators, Implantable Cardiac Pacemakers, Ventricular Assist Devices, Implantable Heart Monitors/Insertable Loop Recorders, Neurostimulators, Implantable Hearing Devices, Others), By End Users (Hospitals, Ambulatory Surgery Center, Specialty Clinics, Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In March 2024, Stryker completed its acquisition of SERF SAS, a France-based joint replacement company. Katherine Truppi, President of Stryker's Joint Replacement division, highlighted that this move enhances its global portfolio and commitment to orthopaedic excellence, expressing enthusiasm for the future collaboration with the SERF SAS team.
In August 2022, Medtronic plc introduced an investigational extravascular implantable cardioverter defibrillator (EV ICD) system with the lead positioned under the breastbone, outside of the heart and veins. This system achieved a defibrillation success rate of 98.7% and met its safety endpoints in a global clinical trial.
In February 2022, Abbott launched patient implants of its dual-chamber leadless pacemaker system as part of the AVEIR DR i2i pivotal clinical study. This investigational aveir dual-chamber leadless pacemaker marks a significant technological advancement in leadless pacing and is the first of its kind to be implanted globally within the pivotal trial.
In December 2021, Royal Philips acquired Vesper Medical Inc., a U.S-based company that specializes in minimally-invasive peripheral vascular devices. This acquisition will enhance Philips’ portfolio with advanced venous stents for treating deep venous disease.